Neurocrine Biosciences (NBIX) Payables (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Payables of $808.3 million for Q2 2026, up 65.13% year-over-year from $489.5 million in Q2 2025, and up 4.57% on a QoQ basis from $773.0 million in Q1 2026.
Neurocrine Biosciences (NBIX) Payables (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Payables for 17 years, with the latest figure at $808.3 million in Q2 2026.
- Payables for Q2 2026 came in at $808.3 million, up 65.13% year-over-year; the trailing twelve-month figure through Jun 2026 was $808.3 million (up 65.13% YoY), and the FY2025 annual result was $674.3 million, up 46.08% from the prior year.
- Payables rose to $808.3 million in Q2 2026, from $773.0 million in the prior quarter.
- Over five years, Payables peaked at $808.3 million in Q2 2026 and troughed at $235.9 million in Q1 2022.
- A 5-year average of $460.0 million and a median of $433.0 million in 2023 frame the typical range for Payables.
- The widest annual swing landed in 2023, when Payables surged 68.91%; it then declined 21.93% in 2024.
- A 5-year view of Payables shows it stood at $347.6 million in 2022, then grew by 29.11% to $448.8 million in 2023, then climbed by 2.85% to $461.6 million in 2024, then surged by 46.08% to $674.3 million in 2025, then gained by 19.87% to $808.3 million in 2026.
- Per Business Quant data, the three most recent Payables figures were $808.3 million in Q2 2026, $773.0 million in Q1 2026, and $674.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -7.73 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 986.00 Mn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 332.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 808.30 Mn |
| Mar 31, 2026 | 773.00 Mn |
| Dec 31, 2025 | 674.30 Mn |
| Sep 30, 2025 | 584.30 Mn |
| Jun 30, 2025 | 489.50 Mn |
| Mar 31, 2025 | 475.20 Mn |
| Dec 31, 2024 | 461.60 Mn |
| Sep 30, 2024 | 392.70 Mn |
| Jun 30, 2024 | 358.50 Mn |
| Mar 31, 2024 | 417.20 Mn |
| Dec 31, 2023 | 448.80 Mn |
| Sep 30, 2023 | 503.00 Mn |
| Jun 30, 2023 | 391.60 Mn |
| Mar 31, 2023 | 355.70 Mn |
| Dec 31, 2022 | 347.60 Mn |
| Sep 30, 2022 | 297.80 Mn |
| Jun 30, 2022 | 265.70 Mn |
| Mar 31, 2022 | 235.90 Mn |
| Dec 31, 2021 | 225.80 Mn |
| Sep 30, 2021 | 205.90 Mn |